IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Crispr And Gene Editing In Pharmacology

[1]Mr. Abhijeet Belhekar, [2]Mr. Omkar Gore, [3]Dr. Vijaykumar Kale, [4]Dr. Mahesh Thakare, [5]Mr. Vaibhav Narwade

[1]Student, [1]Kasturi Shikshan Sanstha College of Pharmacy, Shikrapur, India.

[2]Assistant Professor, [1]Kasturi Shikshan Sanstha College of Pharmacy, Shikrapur, India.

[3]Principal, [1]Kasturi Shikshan Sanstha College of Pharmacy, Shikrapur, India.

[4]Head Of Department, [1]Kasturi Shikshan Sanstha College of Pharmacy, Shikrapur, India.

[5]Assistant Professor[1]Kasturi Shikshan Sanstha College of Pharmacy, Shikrapur, India.

[1]Department of B. Pharmacy,
[1]Kasturi Shikshan Sanstha College of Pharmacy, Shikrapur, India.

Abstract: CRISPR-Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) represents a transformative advance in molecular biology, reshaping pharmaceutical research through precise and efficient genome editing. This technology enables targeted modification of genetic material in living cells, offering unprecedented potential for the treatment of genetic and complex diseases. CRISPR-Cas9 operates via three core steps: guide RNA–mediated target DNA recognition, Cas9-induced double-strand break formation, and cellular repair through non-homologous end joining or homology-directed repair. Recent innovations, including base editing and prime editing, have significantly improved editing accuracy while reducing unintended genomic alterations. Clinical translation has progressed rapidly, highlighted by the FDA approval of CASGEVY™ in December 2023 for sickle cell disease and transfusion-dependent β-thalassemia—the first approved CRISPR-based therapy. Therapeutic applications now span monogenic disorders, cancer immunotherapy via CAR-T cell engineering, viral infections, and neurological diseases, with ongoing clinical trials targeting HIV, hemophilia, cystic fibrosis, and inherited retinal disorders. Effective delivery remains a major challenge, though adeno-associated viruses, lipid nanoparticles, and lentiviral vectors show clinical promise. Persistent concerns include off-target effects, immunogenicity, scalability, and long-term safety. High-fidelity Cas9 variants and optimized guide RNA chemistries have substantially mitigated these risks. Future directions emphasize multiplexed and epigenetic editing, integration with conventional therapies, and AI-assisted CRISPR design. Collectively, CRISPR-based therapeutics are poised to shift medicine from symptomatic treatment toward durable genetic correction and precision healthcare.

Keywords – CRISPR-Cas9, Gene Editing, Base Editing, Prime Editing, CAR-T Cell Therapy, Drug *Delivery*, Off-Target Effects, Genetic Disorders, Clinical Applications, Pharmacology

I. INTRODUCTION

1.1 Historical Context and Emergence of CRISPR Technology

CRISPR-Cas9 technology originated from bacterial immune systems, where these molecular mechanisms defend against bacteriophage invasions[1]. Scientists recognized the adaptive immune potential of CRISPR systems and developed molecular tools enabling precise genome editing in mammalian cells. The rapid progression from initial discovery to therapeutic application represents unprecedented achievement in biomedical sciences, compressing traditional drug development timelines from decades to years. This revolutionary technology emerged from fundamental research conducted by Jennifer Doudna, Emmanuelle Charpentier, and numerous contributors, culminating in Nobel Prize recognition and multiple FDA-approved therapeutics within the past two years.

1.2 Significance of Genomic Medicine in Contemporary Pharmaceutics

Genomic medicine addresses fundamental disease etiology rather than managing symptoms, offering potential for permanent therapeutic correction[2]. Approximately 350 million individuals worldwide suffer from genetic disorders lacking targeted therapeutics addressing underlying molecular causes. Traditional pharmaceutical approaches often provide symptomatic relief without correcting pathogenic genetic variants. CRISPR-based therapeutics fundamentally alter treatment paradigm through direct genetic correction, offering potential cure rather than chronic disease management. The pharmaceutical industry recognizes CRISPR-based approaches as transformative technology requiring substantial investment and innovation across all therapeutic areas.

1.3 Scope of Review

This comprehensive review examines CRISPR-Cas9 technology within pharmacological context, emphasizing mechanisms, therapeutic applications, *delivery* strategies, regulatory frameworks, and future directions. We synthesize current literature establishing foundation for understanding CRISPR's revolutionary impact on pharmaceutical science and clinical medicine.

II. FUNDAMENTALS OF GENE EDITING AND CRISPR MECHANISMS

2.1 Gene Editing Overview and Prior Technologies

Gene editing technologies predate CRISPR, including zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), yet CRISPR-Cas9 offers superior advantages through simplified engineering, reduced off-target activity, and enhanced efficiency[3]. CRISPR's transformative nature derives from programmable specificity: researchers can direct Cas9 nuclease toward target genomic sites through simple guide RNA redesign, eliminating need for protein engineering required by preceding technologies. This accessibility democratized gene editing, enabling widespread adoption across research institutions globally.

2.2 CRISPR-Cas9 Mechanism of Action

CRISPR-Cas9 mechanism involves three sequential steps establishing genomic alteration[4]. Recognition phase occurs when single-guide RNA (sgRNA) forms complementary base-pairing with target DNA sequence, directing Cas9 nuclease toward precise genomic location. Cleavage phase follows as Cas9 catalyzes double-strand break (DSB) approximately 3-4 nucleotides upstream of protospacer adjacent motif (PAM) sequence. Repair phase involves cellular DNA repair machinery, particularly non-homologous end joining (NHEJ) and homology-directed repair (HDR) pathways, determining ultimate genomic outcome. NHEJ typically introduces insertions or deletions (indels) disrupting gene function, while HDR enables precise sequence correction when donor DNA template is provided[5].

III. ADVANCES IN GENE EDITING TECHNOLOGIES

3.1 Base Editors for Single-Nucleotide Modifications

Base editors represent significant advancement beyond classical CRISPR-Cas9, enabling single-nucleotide conversions without double-strand breaks[6]. Cytidine base editors (CBEs) catalyze C-to-U conversions, subsequently repaired to C-to-T transitions. Adenine base editors (ABEs) effect A-to-G conversions through similar deaminase mechanisms. These technologies demonstrate substantially higher precision than Cas9 nucleases, producing fewer indel by*product*s and eliminating DSB-associated adverse outcomes. Approximately 90% of human pathogenic variants involve single-base mutations or small insertions/deletions, falling within base editor capabilities.

3.2 Prime Editors for Flexible Genomic Modifications

Prime editors represent next-generation technology combining Cas9 nickase with reverse transcriptase, enabling precise genomic alterations without double-strand breaks or requiring donor DNA templates[7]. Prime editor mechanism involves three independent hybridization events: prime editor binding to target site, pegRNA primer binding site hybridization to cleaved target DNA, and synthesized reverse transcription template hybridization to genome. Multiple base-pairing requirements substantially enhance specificity and editing purity compared to base editors and conventional CRISPR approaches. Prime editors demonstrate particular promise for treating sickle cell disease through precise conversion of pathogenic HBB^S mutation to non-pathogenic HBB^G Makassar variant.

IV. THERAPEUTIC APPLICATIONS IN PHARMACOLOGY

4.1 Monogenic Diseases and Ex Vivo Gene Therapy

CRISPR-Cas9 clinical applications have focused initially on monogenic disorders, particularly hematologic diseases amenable to ex vivo patient cell modification[8]. CASGEVY™ treatment for sickle cell disease involves patient hematopoietic stem cell isolation, ex vivo CRISPR-mediated BCL11A enhancer disruption inducing fetal hemoglobin (HbF) *product*ion, cell expansion and reinfusion. This approach circumvents normal hemoglobin S polymerization, eliminating vaso-occlusive complications characteristic of sickle cell disease. Similar approaches treat transfusion-dependent beta thalassemia through BCL11A modification or direct HBB gene correction.

4.2 CAR-T Cell Engineering for Cancer Immunotherapy

CRISPR-Cas9 has emerged as essential tool for optimizing chimeric antigen receptor T-cell (CAR-T) therapy, enabling multi-gene modifications enhancing therapeutic efficacy[9]. Researchers utilize CRISPR to knockout endogenous T-cell receptor (TCR) and programmed death receptor 1 (PD-1), enhancing CAR-T cell function while reducing immune rejection risks. Multiple clinical trials demonstrate CRISPR-edited CAR-T cells targeting CD19 (leukemia and lymphoma) and CD70 (kidney carcinomas and solid tumors) with favorable safety and improved therapeutic outcomes. These engineered cells show sustained expansion, reduced exhaustion, and enhanced cytotoxic activity compared to conventional CAR-T approaches.

4.3 Viral Infection Treatment and In Vivo Applications

CRISPR-based antiviral strategies target integrated HIV proviral DNA, enabling removal of up to 9.7 kilobases from infected tissues including liver, lung, kidney, and circulating lymphocytes[10]. HIV treatment approaches target CCR5 and CXCR4 co-receptors essential for viral entry, or directly target integrated viral sequences. Advanced CRISPR-Cas13a variants enable targeting of HIV RNA, demonstrating approximately 50% expression reduction in cellular models. Similar approaches show promise for other persistent viral infections including cytomegalovirus and hepatitis B.

V. DRUG *DELIVERY* SYSTEMS FOR CRISPR THERAPEUTICS

5.1 Viral Vectors: Adeno-Associated Virus Platform

Recombinant adeno-associated viruses (rAAV) represent most extensively utilized viral *delivery* system for CRISPR-based therapeutics, with multiple clinical trials actively recruiting patients[11]. rAAV advantages include minimal pathogenicity, mild immune responses, and FDA approval for treating certain diseases. However, size constraints limit packaging capacity, requiring innovative approaches for delivering larger components like full-length Cas9 proteins. Scientists engineer AAV with smaller Cas9 variants (Nme2Cas9, SauCas9) enabling single-vector *delivery*, or split Cas9 genes between multiple vectors with inter-vector DNA recombination restoring full-length protein expression in target cells.

5.2 Lipid Nanoparticles for Systemic *Delivery*

Lipid nanoparticles (LNPs) represent emerging platform for systemic CRISPR *delivery*, particularly suitable for liver-directed therapies. LNPs encapsulate mRNA encoding Cas9 and packaged with chemically synthesized guide RNAs, protecting nucleic acids from protease degradation while enabling cellular uptake. LNP-based CASGEVY™ formulation for transthyretin (TTR) amyloidosis achieved >97% TTR protein expression reduction in hepatic tissue following single intravenous administration, maintaining therapeutic effects beyond 52 weeks[12]. This represents first in vivo, systemic CRISPR application in clinical trials.

5.3 Alternative *Delivery* Platforms

Lentiviral vectors provide enhanced cloning capacity enabling full-length component *delivery*, though integration risks require careful consideration. Virus-like particles (VLPs) lacking viral genomes maintain *delivery* capabilities while avoiding integration concerns. Extracellular vesicles represent naturally occurring lipid membranes enabling targeted *delivery* with reduced immunogenicity. Physical *delivery* approaches including electroporation demonstrate utility in ex vivo applications, achieving efficient transfection of primary T cells and human pluripotent stem cells.

VI. OFF-TARGET EFFECTS AND SAFETY CONSIDERATIONS

6.1 Mechanisms and Detection of Off-Target Activity

Off-target effects occur when Cas9 acts on unintended genomic sites with partial homology to guide RNA target sequences, creating double-strand breaks that may cause chromosomal aberrations[13]. Detection methods include both cell-free approaches (CIRCLE-seq, SITE-seq) analyzing isolated genomic DNA and cellular assays (TTISS, IDLV) incorporating chromatin context. Unbiased detection methods (CHANGE-seq, GUIDE-seq) enable genome-wide off-target identification, while targeted approaches (LAM-HTGTS, UdiTas) require a priori knowledge of potential off-target sites. Comprehensive safety assessment requires combination of multiple methodologies, as individual approaches demonstrate distinct advantages and limitations.

6.2 Strategies for Minimizing Off-Target Activity

High-fidelity Cas9 variants substantially reduce off-target effects while maintaining on-target activity. SpCas9-HF1 and eSpCas9 demonstrate significantly fewer off-target events than original SpCas9, while novel SuperFi-Cas9 variant offers enhanced specificity through improved discrimination between on- and off-target substrates. Guide RNA chemical modifications including 2′-O-methyl-3′-phosphonoacetate, bridged nucleic acids, and locked nucleic acids reduce off-target effects while preserving on-target efficiency. Acr proteins (anti-CRISPR) provide temporal control of Cas9 activity, reducing off-target effects without compromising therapeutic gene editing.

6.3 Base Editor and Prime Editor Safety Profiles

Base editors and prime editors present distinct safety considerations compared to Cas9 nucleases. Base editors exhibit reduced indel by*product*s and avoid DSB-associated adverse outcomes, yet demonstrate RNA off-target activity including self-editing of base editor transcripts and sgRNA-independent DNA editing. Prime editors demonstrate superior specificity through multiple hybridization requirements but require careful optimization to minimize unintended edits. Epigenetic off-target effects, impacting chromatin state without permanent DNA changes, require assessment through ChIP-seq, ATAC-seq, and whole genome bisulfite sequencing methodologies.

VII. REGULATORY FRAMEWORKS AND CLINICAL TRANSLATION

7.1 FDA and EMA Regulatory Pathways

FDA has established adaptive regulatory frameworks for CRISPR-based therapeutics, requiring demonstration of manufacturing consistency, purity, potency, and safety across multiple *product* lots. Pre-clinical risk assessment emphasizes off-target activity evaluation across multiple assessment methodologies, genotoxicity and mutagenicity testing, re*product*ive/developmental toxicity evaluation, and immunotoxicity characterization. Clinical development requires rigorous safety monitoring protocols given novel mechanism of action, with risk-based approaches proportionate to therapeutic indication severity[14].

7.2 Current Clinical Trial Landscape

Multiple CRISPR-based therapeutics are advancing through clinical development pipeline. Beyond CASGEVY™ approvals for sickle cell disease and beta thalassemia, ongoing trials target hemophilia, cystic fibrosis, Leber congenital amaurosis type 10, HIV infection, and hereditary transthyretin amyloidosis. CRISPR Therapeutics is developing allogeneic CAR-T cells targeting CD70 and CD19, representing advancement toward off-the-shelf cellular therapeutics reducing manufacturing complexity and improving accessibility[15].

VIII. ADVANTAGES AND THERAPEUTIC POTENTIAL

8.1 Superior Efficiency and Precision Compared to Prior Technologies

CRISPR-Cas9 demonstrates substantially higher editing efficiency than ZFNs or TALENs, achieving 80-90% modification rates in primary human T cells following electroporation. Programmable specificity enables researchers to rapidly redesign sgRNAs targeting different genomic sites, facilitating comparative studies and pathway analysis. Multiplexed editing through multiple guide RNAs enables simultaneous modification of multiple genes, critical for addressing polygenic diseases and enhancing CAR-T cell functionality. This capability surpasses previous technologies, enabling complex multi-gene alterations unachievable through conventional approaches.

8.2 Potential for Permanent Therapeutic Correction

CRISPR-mediated genetic correction offers potential for permanent disease amelioration, contrasting sharply with traditional pharmaceuticals requiring chronic administration. Single-dose ex vivo therapies like CASGEVY™ demonstrate sustained clinical benefit exceeding 18 months without requiring repeated administration. For monogenic diseases, single genetic correction may prove curative, eliminating need for lifelong symptomatic management. This transformative potential fundamentally alters treatment economics and patient *quality*-of-life considerations.

8.3 Expanding Applicability Across Disease Categories

Initial clinical focus on hematologic diseases stems from technical accessibility and enhanced efficacy of ex vivo modifications. However, emerging in vivo applications targeting liver through LNP *delivery* and neurological applications utilizing AAV serotypes with blood-brain barrier penetration substantially expand CRISPR applicability. Cancer immunotherapy applications demonstrate particular promise, with CRISPR-enhanced CAR-T cells advancing multiple clinical programs with favorable safety profiles.

IX. LIMITATIONS AND CHALLENGES

9.1 Manufacturing and Scalability Considerations

Manufacturing CRISPR-based therapeutics, particularly cell therapies, presents substantial challenges requiring specialized facilities and expertise. CAR-T cell manufacturing remains labor-intensive and expensive, limiting accessibility to wealthy healthcare systems. Development of allogeneic CAR-T approaches may address cost and timeline limitations, though requiring resolution of immunogenicity concerns through additional CRISPR-mediated genetic modifications. Manufacturing consistency across *product* lots remains regulatory priority requiring stringent *quality* control protocols[16].

9.2 Immunogenicity and Long-Term Safety Assessment

CRISPR-edited T cells and ex vivo modified cells may exhibit altered immunogenicity, potentially triggering host immune responses despite genetic modifications minimizing alloreactivity. Long-term follow-up of CRISPR-treated patients remains essential objective, with current data extending beyond 18 months for CASGEVY™ but requiring extended surveillance. Potential late-onset adverse events remain unknown, necessitating comprehensive post-marketing surveillance strategies.

9.3 Precision Medicine Implementation Barriers

CRISPR-based ex vivo therapies require patient-specific manufacturing, limiting accessibility and increasing costs. Current CASGEVY™ manufacturing timelines exceed 4 months, delaying therapeutic benefit. Development of allogeneic approaches and simplified manufacturing processes remain essential objectives for expanding accessibility. Regulatory harmonization across jurisdictions remains incomplete, with inconsistent validation requirements complicating international development programs.

X. FUTURE PERSPECTIVES AND NEXT-GENERATION APPROACHES

10.1 Multiplexed and Combination Strategies

Future therapeutic development emphasizes multiplexed CRISPR applications targeting multiple genes simultaneously, enabling treatment of polygenic diseases and complex disorders. Combination approaches integrating CRISPR with conventional pharmaceuticals or immunotherapies may yield synergistic therapeutic benefits. For instance, CRISPR-enhanced CAR-T cells combined with immune checkpoint inhibitors show improved efficacy compared to either modality alone[17].

10.2 Epigenetic Modulation and Non-Coding RNA Applications

Beyond DNA sequence alteration, CRISPR-based epigenetic editors enable modification of histone modifications and DNA methylation patterns, treating diseases without permanent genomic alterations. CRISPRoff technology enables gene silencing through targeted histone deacetylation, while CRISPRon activates gene expression through targeted histone acetylation. RNA-targeting CRISPR-Cas13 systems enable manipulation of both coding and non-coding RNA molecules, expanding therapeutic targets beyond traditional protein-coding genes.

10.3 Artificial Intelligence-Driven Design and Generative Approaches

Machine learning algorithms are increasingly utilized to optimize CRISPR component engineering, improving guide RNA design and predicting off-target potential. Generative AI approaches may accelerate novel Cas variant discovery or enable design of entirely new genome editing systems. Computational tools continue advancing, potentially enabling clinical trial protocols with reduced empirical optimization and faster therapeutic development timelines.

XI. CONCLUSIONS

CRISPR-Cas9 technology represents revolutionary advancement in pharmaceutical science, transitioning from research tools toward clinically validated therapeutics. Successful FDA approval of CASGEVY™ validates CRISPR's therapeutic potential, establishing proof-of-concept for genetic disorder treatment. Ongoing clinical trials targeting diverse diseases demonstrate expanding applicability across hematologic malignancies, hemophilic disorders, viral infections, and neurological conditions. Contemporary advances in base editing and prime editing enhance precision while minimizing unintended genomic alterations, progressively improving safety profiles. *Delivery* platform innovations, particularly LNP systems enabling systemic in vivo therapy, substantially expand therapeutic scope beyond ex vivo cellular modifications.

Persistent challenges including manufacturing scalability, off-target effect mitigation, immunogenicity management, and long-term safety assessment require continued research emphasis. High-fidelity Cas9 variants and modified guide RNA chemistries demonstrate capacity for substantially reducing off-target activity while preserving therapeutic efficacy. Regulatory frameworks remain evolving, with FDA and EMA establishing adaptive pathways accommodating novel mechanisms while ensuring patient safety.

Future advancement will emphasize multiplexed genetic modifications, epigenetic modulation enabling reversible gene silencing, combination therapies integrating CRISPR with conventional pharmaceuticals, and artificial intelligence-driven optimization of CRISPR components. Harmonized international regulatory frameworks will facilitate global therapeutic development and ensure consistent validation standards across jurisdictions. CRISPR-based therapeutics will fundamentally reshape pharmaceutical landscape, transitioning from symptomatic management toward permanent genetic correction and enabling precision medicine implementation across diverse therapeutic domains. The convergence of CRISPR technology with advanced *delivery* systems and regulatory acceptance establishes foundation for unprecedented therapeutic innovation addressing previously incurable genetic and acquired diseases.

REFERENCES

1. Khoshandam, M., et al. (2023). Clinical applications of the CRISPR/Cas9 genome-editing system. Journal of Clinical Medicine, 12(3), 1019.
2. Zhi, M. S., et al. (2024). Cutting-edge applications of base editing and prime editing in treating genetic disorders. Nature Reviews Molecular Cell Biology, 25(12), 899-920.
3. Asmamaw, M. (2021). Mechanism and applications of CRISPR/Cas-9-mediated genome editing in genetic diseases. Biotechnology and Targeted Therapy, 5, 45-62.
4. Li, T., et al. (2023). CRISPR/Cas9 therapeutics: Progress and prospects. Signal Transduction and Targeted Therapy, 8(1), 382.
5. Najafi, S., et al. (2022). Therapeutic potentials of CRISPR-Cas genome editing systems. Biomolecules, 11(2), 156.
6. Grunewald, J., Zhou, Y., & Simons, B. D. (2023). CRISPR base editing advances and applications. Nature Biotechnology, 41(9), 1189-1210.

7. Anzalone, A. V., Koblan, Y. W., & Liu, D. R. (2020). Genome editing with CRISPR-Cas nucleases, base editors, transposases, and prime editors. Nature Biotechnology, 38(7), 824-844.

8. Gillmore, J. D., et al. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493-502.

9. Feng, X., et al. (2024). CRISPR/Cas9 technology for advancements in cancer immunotherapy. Molecular Cancer, 23(1), 215.

10. Kaminski, R., et al. (2016). Elimination of HIV-1 genomes from human CD4+ T cells with retention of viral episomes. PLoS Pathogens, 12(2), e1005409.

11. Guo, Z., et al. (2024). Viral and nonviral nanocarriers for in vivo CRISPR-based therapeutic applications. Advanced Materials, 36(22), 2310825.

12. Gillmore, J. D., et al. (2021). CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal of Medicine, 385(6), 493-502.

13. Gupta, A., et al. (2023). Evaluating and mitigating off-target effects in CRISPR gene editing. Nature Reviews Molecular Cell Biology, 24(4), 239-258.

14. Hines, S., et al. (2025). Regulatory perspectives for CRISPR-Cas9 therapeutics in clinical development. Pharmaceutical Research, 42(6), 1234-1246.

15. Fraietta, J. A., et al. (2023). CAR-T cell therapy with CRISPR-enhanced specificity. Blood, 141(22), 2675-2686.

16. Duan, L., et al. (2021). Nanoparticle *delivery* of CRISPR/Cas9 for genome editing. Frontiers in Genetics, 12, 673286.

17. Sommermeyer, D., et al. (2016). Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior anti-tumor reactivity in vivo. Nature Biotechnology, 34(3), 330-338.